Cancer treatment has advanced significantly with the development of targeted therapies, and mTOR inhibitors are among the most important innovations in this field. These drugs focus on blocking a key pathway that cancer cells use to grow, multiply, and survive. By interfering with this process, mTOR inhibitors help slow or stop tumor progression and improve outcomes for certain cancer patients.
The mammalian target of rapamycin (mTOR) is a protein that regulates essential cellular functions such as growth, metabolism, and protein synthesis. In many cancers, the mTOR signaling pathway becomes overactive, causing uncontrolled cell division and tumor development. mTOR inhibitors work by blocking this pathway, which reduces cancer cell growth and limits the tumor’s ability to spread.
One of the earliest and most well-known mTOR inhibitors is sirolimus, originally developed as an immunosuppressant for organ transplant patients. Researchers later discovered its ability to block cancer cell growth, leading to the development…